Novo Nordisk Signs $2.6B Deal With Hengrui For Oral GLP-1

Novo Nordisk's $300 million upfront commitment for HRS-1596 signals that oral peptide manufacturing is moving from a formulation curiosity to a pipeline priority, and the supply chain infrastructure required to support once-weekly oral GLP-1/GIP dosing at commercial scale does not yet exist in standardised form. Under the exclusive license agreement announced 29 September 2026, Novo acquires global rights to develop, manufacture, and commercialise HRS-1596 outside mainland China, Hong Kong, Macao, and Taiwan, with total deal value reaching up to $2.6 billion USD contingent on development, regulatory, and commercial milestones.

HRS-1596 is a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist designed to reduce weight and improve glycaemic control through appetite suppression, insulin secretion stimulation, and improved insulin sensitivity. Hengrui Pharma has already received approval in China to initiate Phase 1 clinical trials for weight management and type 2 diabetes, providing Novo with a near-term entry point into the development programme rather than a preclinical starting position.

For plant heads and formulation leads, the manufacturing read is consequential. Once-weekly oral peptide delivery demands precision in bioavailability enhancement, permeation enhancers, protective excipient matrices, and tightly controlled dissolution profiles, none of which transfer directly from injectable GLP-1 manufacturing platforms. CDMO partners with oral solid dose peptide capability will face early capacity pressure as Novo and its peers accelerate competing programmes through 21 CFR Part 211-compliant development pipelines. Process validation strategies will need to account for the sensitivity of peptide APIs to moisture, temperature, and mechanical stress during tablet or capsule manufacture.

The agreement remains subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, with transaction close expected in Q4 2026. Hengrui retains royalty eligibility on net sales within the licensed territory, preserving a commercial stake aligned with long-term volume performance rather than milestone payments alone.

For QA directors, the handoff of a phase 1-ready asset across jurisdictions introduces immediate technology transfer considerations: Hengrui's existing China-based manufacturing data, analytical methods, and release specifications will need to be assessed for alignment with ICH Q10 quality system expectations and Novo's own process validation frameworks before any ex-China clinical supply can be initiated.

The first measurable checkpoint will be Novo's submission of an Investigational New Drug application or equivalent regulatory filing in a licensed territory, which will test how efficiently the two organisations can execute cross-border technology transfer on a novel oral peptide platform.

Source: Novo Nordisk via GlobeNewswire, 29 September 2026.